BioSpace News Archive

Conformal Medical, Inc. announced the positive one-year results from the company’s CONFORMAL Early Feasibility Study.

A retrospective study undertaken by Maccabi KSM Research in Israel has revealed that the Pfizer COVID-19 vaccine offers the same level of protection against the virus for patients with Celiac Disease as it does for those without this chronic condition.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Entrinsic Bioscience has published a ground-breaking clinical study demonstrating the potential for next generation sports and rehydration beverages, powered by its new Ultra-Hydrating HeatDefense™ formula which promotes dual action rapid rehydration with new levels of heat protection during sports, physical exertion and high heat stress.

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 31, 2023 at 8:30 a.m. Eastern Time to report its third quarter 2023 financial results and recent portfolio execution.

Aprea Therapeutics, Inc. announced it will host a KOL event on Tuesday, October 31, 2023 at 11:00 am ET. The program will feature Dr. Fiona Simpkins, Perelman School of Medicine, University of Pennsylvania, and Dr. Timothy A. Yap, University of Texas MD Anderson Cancer Center, who will discuss the current landscape of treatments and investigational drugs for patients with advanced solid tumors and their role in tumor suppression.

Foghorn® Therapeutics Inc. (Nasdaq: FHTX) today announced that the Company will present new data from multiple preclinical and clinical programs at the 6th Annual Targeted Protein Degradation (TPD) Summit and the Connective Tissue Oncology Society (CTOS) Annual Meeting.

Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today announced new preclinical in vitro data on TSHA-102 in Rett syndrome as part of a poster presentation at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress.

ASLAN management will present additional analyses from the TREK-AD study and new market research from prescriber and patient surveys on the AD treatment landscape.

Cordis has announced completion of patient enrollment in SUCCESS PTA, its large post-market study with the SELUTION SLR™ Drug-Eluting Balloon (DEB) for the treatment of patients with peripheral artery disease (PAD).